Two epigenetic regulators interfere with healthy aging

- Posted by admin in English

It has long been assumed that lifespan and health are strongly correlated, but although there has been an overall increase in human life expectancy in recent decades, it is too often accompanied by deterioration of health.

A new study published on February 26 in Nature shows the influence of two epigenetic regulators on aging. Scientists led by Jie Yuan from the Chinese Academy of Sciences in Shanghai have studied the BAZ-2 and SET-6 proteins in Caenorhabditis elegans worms, which are orthologs of the human proteins BAZ2B and EHMT1.

Through genome-wide RNA-interference-based screening of genes that regulate behavioral deterioration in aging C. elegans, the researchers identified 59 genes as potential health modulators during aging. Essentially the proteins expressed by these genes, read and write epigenetic signals.

Among these modulators, they found that a neuronal epigenetic reader, BAZ-2, and a neuronal histone SET-6, accelerate the deterioration of the behavior of C. elegans by reducing the mitochondrial function, and repressing the expression of the encoded mitochondrial proteins. in the cell nucleus.

The researchers found that the levels of the two proteins increase with age in C. elegans and mice, which in turn attenuates the expression of genes involved in mitochondrial function.

BAZ-2 and SET-6 are complementary epigenetic mechanisms. SET-6 is an "epigenetic writer" and BAZ-2 is an "epigenetic reader" which recognizes modified histones and recruits transcriptional regulators.

Histones are proteins located in the nucleus of eukaryotic cells. They are the main protein components of chromosomes. They are closely associated with DNA and allow their compaction, but they also modify the expression of proteins by various epigenetic mechanisms known as the "histone code".

enter image description here Source Wikipedia.

How do BAZ-2 and SET-6 accelerate aging? The researchers found that the two proteins bind together to the promoter regions of more than 2,000 genes, and decrease their expression via methylation of histones. Among these target genes are many mitochondrial genes encoded nuclear. By suppressing the expression of these genes, BAZ-2 and SET-6 reduce oxygen consumption and ATP production, and decrease the critical stress responses that maintain mitochondrial proteostasis. The resulting metabolic slowdown discourages the worms from assimilating their food and they mate less.

This mechanism is conserved in the neurons of cultured mice and human cells. What about the orthologs of these epigenetic proteins in humans? A review of the databases shows that expression by human orthologs of the two proteins mentioned above, BAZ2B and EHMT1, increases with age and is positively correlated with the progression of Alzheimer's disease. Researchers have verified that ablation of BAZ-2 mouse ortholog Baz2b attenuates age-dependent body weight gain and prevents cognitive decline in aging mice.

enter image description here While wild-type mice grew fat with age, animals lacking both copies of the epigenetic reader Baz2b stayed trim, indicating improved mitochondrial function. [Yuan et al., Nature, 2020.]

However, it must be asked whether BAZ-2 and SET-6 would rather mediate age-related physiological adaptation, rather than the agents of aging itself. Indeed their action could reflect a mechanism of adaptation to a progressively more hostile biological environment.

Old Article 5

- Posted by system in English

Old Article 4

- Posted by system in English

Old Article 3

- Posted by system in English

Old Article 2

- Posted by system in English

Old Article 1

- Posted by system in English

Significance of the Topic:

The study of sensory processing in autism spectrum disorder (ASD) is crucial due to its impact on an individual's quality of life. Up to 95% of autistic individuals experience sensory processing differences, which can lead to difficulties in social interactions, communication, and daily functioning. Understanding the complex relationship between hyper- and hyporesponsivity to sensory stimuli in ASD can provide valuable insights into the neural mechanisms underlying this condition.

Importance:

The study's findings have significant implications for the diagnosis, management, and treatment of ASD. By acknowledging the co-occurrence of hyper- and hyporesponsivity, clinicians can develop more comprehensive and targeted interventions that address the individual's unique sensory processing needs. This can improve the quality of life for autistic individuals and their families.

Timeliness:

The study's focus on the complex relationship between sensory hyper- and hyporesponsivity in ASD is especially timely. Recent advances in neuroimaging and computational modeling have enabled researchers to better understand the neural mechanisms underlying sensory processing. This study contributes to the growing body of research in this area, providing new insights that can inform the development of effective treatments and interventions.

Relevance:

The study's findings have relevance beyond ASD, as they may also apply to a broader range of neurological, psychiatric, and developmental conditions characterized by sensory processing difficulties. The "Sensory Paradox" framework proposed by the study offers a new perspective on sensory processing, which can be applied to various conditions, including ADHD, anxiety disorders, and intellectual disabilities.

Analysis of the Text:

  1. Background: The study begins by establishing the significance of sensory processing in ASD, highlighting the prevalence and impact of sensory processing differences in autistic individuals.
  2. Methods: The researchers describe their methodology, which involves assessing sensory hyper- and hyporesponsivity in 3-4-year-old children with ASD and typically developing children.
  3. Findings: The study reports a positive correlation between sensory hyper- and hyporesponsivity within and across sensory modalities, which the researchers term the "Sensory Paradox."
  4. Interpretation: The study's authors interpret the findings in the context of previous literature, suggesting that the "Sensory Paradox" provides a new framework for understanding sensory processing in ASD and other neurodevelopmental disorders.
  5. Funding: The study acknowledges the funding agencies that supported the research, highlighting the importance of continued funding for autism research.
  6. Research in Context: The study provides an overview of the existing literature on sensory processing in ASD, highlighting the need for a more comprehensive understanding of this complex phenomenon.
  7. Added Value: The study emphasizes the novel finding of the positive correlation between sensory hyper- and hyporesponsivity, which offers a new perspective on sensory processing.
  8. Implications: The study's authors discuss the implications of their findings for the diagnosis, management, and treatment of ASD, as well as their potential relevance to other neurological, psychiatric, and developmental conditions.

Usefulness for Disease Management or Drug Discovery:

The study's findings have significant implications for the development of effective treatments and interventions for ASD. By understanding the complex relationship between sensory hyper- and hyporesponsivity, clinicians can develop more targeted and comprehensive approaches to addressing sensory processing difficulties. This can improve the quality of life for autistic individuals and their families.

Originality:

The study's finding of the positive correlation between sensory hyper- and hyporesponsivity is a novel contribution to the field. While previous studies have identified both hyper- and hyporesponsivity in ASD, the study's emphasis on the co-occurrence of these two phenomena offers a new perspective on sensory processing.

Comparison with the State of Art:

The study's findings are consistent with previous research on sensory processing in ASD, which has highlighted the complex and variable nature of sensory processing difficulties in this population. However, the study's emphasis on the positive correlation between sensory hyper- and hyporesponsivity offers a new framework for understanding sensory processing in ASD and other neurodevelopmental disorders.

Read the original article on medRxiv

Analysis of the Text: Significance, Importance, Timeliness, and Relevance

The text discusses the relationship between plasma glial fibrillary acidic protein (GFAP), a marker of astrocytic activation, and Alzheimer's disease (Alzheimer's disease) in cognitively unimpaired (CU) older adults. The significance of this topic lies in its potential to provide insights into the early detection and monitoring of Alzheimer's disease, a debilitating neurodegenerative disorder affecting millions worldwide.

Importance:

  1. Early detection and prevention: Identifying prognostic biomarkers like GFAP can facilitate early detection and intervention, potentially slowing or preventing cognitive decline.
  2. Personalized medicine: The observed sex-specific vulnerability highlights the importance of considering individual factors, such as sex, in Alzheimer's disease research and treatment.
  3. Development of targeted therapies: Understanding the relationship between GFAP and Alzheimer's disease can inform the development of novel therapeutic approaches targeting astrocytic activation.

Timeliness:

  1. Advancements in Alzheimer's disease research: The study contributes to the growing field of Alzheimer's disease research, which has seen significant progress in recent years.
  2. Emergence of biomarkers: The identification of plasma GFAP as a prognostic biomarker aligns with the increasing focus on developing reliable biomarkers for Alzheimer's disease.

Relevance:

  1. Clinical implications: The findings have implications for the clinical management of Alzheimer's disease, particularly in the early stages of the disease.
  2. Research applications: The study's results can inform future research on the mechanisms underlying Alzheimer's disease and the development of effective treatments.

Analysis of the Text: Relationship between Items

  1. Plasma GFAP: Elevated plasma GFAP is associated with lower cognitive performance, greater amyloid burden, and faster cognitive decline in CU older adults.
  2. Amyloid burden: Higher amyloid burden is linked to elevated GFAP, suggesting a relationship between astrocytic activation and amyloid accumulation in Alzheimer's disease.
  3. Cognitive decline: Plasma GFAP predicts faster cognitive decline, highlighting its potential as a prognostic biomarker for Alzheimer's disease.
  4. Sex-specific vulnerability: The study reveals stronger associations between GFAP and Alzheimer's disease-related outcomes in females, underscoring the importance of considering sex-specific factors in Alzheimer's disease research.

Usefulness for Disease Management and Drug Discovery:

The study provides valuable insights into the relationship between plasma GFAP and Alzheimer's disease, which can inform the development of novel therapeutic approaches targeting astrocytic activation. Elevated GFAP may serve as a prognostic biomarker for Alzheimer's disease, enabling early detection and intervention. The observed sex-specific vulnerability highlights the need to consider individual factors, such as sex, in Alzheimer's disease research and treatment.

Originality of the Text:

The study provides original information by:

  1. Identifying plasma GFAP as a prognostic biomarker: The study demonstrates the predictive value of plasma GFAP in CU older adults, offering a potential new tool for Alzheimer's disease research and diagnosis.
  2. Highlighting sex-specific vulnerability: The findings emphasize the importance of considering sex-specific factors in Alzheimer's disease research and treatment, which is a relatively unexplored area of study.
  3. Investigating longitudinal associations: The study's longitudinal design allows for a more comprehensive understanding of the relationships between plasma GFAP, cognitive decline, and Alzheimer's disease-related outcomes.

Read the original article on medRxiv

BackgroundFirstly, to determine whether iron-sensitive MRI measures mediate neuromelanin (NM) loss within the substantia nigra pars compacta (SNc) and its subregion, nigrosome-1 (N1) in idiopathic Parkinsons disease (iPD) and GBA-associated Parkinsons disease (GBA-PD) versus healthy controls (HC). Secondly, to assess the diagnostic value of NM-and iron MRI metrics, including their lateralisation.

MethodsEighty-six participants (HC=30, iPD = 30, GBA-PD = 26) underwent midbrain quantitative NM-MRI and susceptibility-weighted imaging (SWI). Contrast ratio (CR), normalised volume (nVol) and left-right asymmetry indices (AI) of SNc and N1 calculated. Receiver-operating analyses assessed group discrimination and onset-side prediction. Bidirectional causal mediation (5,000 bootstraps, FDR-corrected) tested Iron[->]NM[->]group and NM[->]Iron[->]group pathways. Moderation models examined the effect of GBA-mutation severity.

ResultsiPD and GBA-PD showed marked NM loss and increased iron in SNc/N1, being more prominent in GBA-PD. N1 NM metrics provided the strongest discrimination (HC vs GBA-PD AUC=0.93, HC vs iPD AUC=0.83), followed by iron measures (AUC=0.78-0.89). N1 NM asymmetry yielded moderate lateralisation accuracy (AUC=0.76). Cross-sectional mediation analyses identified significant Iron[->]NM[->]group effects across SNc and N1 (q<0.01), supporting mechanistic hypotheses of iron-driven NM depletion in PD. In GBA-PD, NM-iron coupling in N1 was influenced by mutation severity, suggesting a genotype-specific disruption of NM-iron homeostasis.

ConclusionsMulti-contrast MRI centered on N1 reveals an iron-driven NM imbalance that distinguishes PD from controls and it is modulated by GBA mutation severity, supporting the applicability of N1-focused NM-iron imaging as a biomarker for PD diagnosis.

Note: This manuscript has been submitted to Journal of Neurology, Neurosurgery & Psychiatry for consideration.

Read the original article on medRxiv

Analysis of the Text: Significance, Importance, Timeliness, and Relevance

The text discusses the emergence of a new blood-based biomarker, plasma tau phosphorylated at threonine 217 (pTau217), for the detection of amyloid-beta (Aβ) burden in Alzheimer's disease (AD). The topic of disease-modifying anti-Aβ therapies for AD has significant implications for the management and treatment of this devastating neurodegenerative disorder.

Importance:

  1. Early detection of AD: The ability to detect AD early and accurately is crucial for the implementation of effective treatment strategies. The emergence of pTau217 as a promising biomarker offers a scalable and minimally invasive diagnostic solution.
  2. Disease-modifying therapies: The success of Aβ-targeting therapies hinges on the early detection of Aβ burden. The accuracy of pTau217 in reflecting Aβ burden could enable clinicians to identify patients who may benefit from these therapies.
  3. Personalized medicine: The development of pTau217 as a biomarker could contribute to a more nuanced understanding of AD pathology and facilitate the development of personalized treatment strategies.

Timeliness:

  1. Growing interest in non-invasive biomarkers: The shift towards non-invasive biomarkers for AD diagnosis is gaining momentum, and the development of pTau217 as a plasma-based biomarker is timely.
  2. Advancements in AD research: The text builds upon the existing knowledge of AD pathology and the role of Aβ in the disease.
  3. Emergence of precision medicine: The use of biomarkers like pTau217 is part of the growing trend towards precision medicine in AD research and treatment.

Relevance:

  1. Clinical utility: The text highlights the potential implementation of pTau217 in routine clinical practice, which could aid early detection of AD.
  2. Research implications: The findings of this study could inform future research on AD pathophysiology and treatment strategies.
  3. Translation to real-world settings: The use of an unselected cohort reflective of clinical practice provides valuable insights into the practical application of pTau217 in various clinical settings.

Usefulness for Disease Management and Drug Discovery:

  1. Early detection: The accuracy of pTau217 in reflecting Aβ burden could enable clinicians to identify patients who may benefit from Aβ-targeting therapies.
  2. Personalized treatment strategies: The development of pTau217 as a biomarker could contribute to a more nuanced understanding of AD pathology and facilitate the development of personalized treatment strategies.
  3. Monitoring treatment response: The use of pTau217 as a biomarker could enable clinicians to monitor treatment response and adjust therapy accordingly.

Originality of Information:

  1. Existing knowledge: The text builds upon the existing knowledge of AD pathology and the role of Aβ in the disease.
  2. Novel application: The use of pTau217 as a plasma-based biomarker is a novel application, and the findings of this study provide valuable insights into its clinical utility.
  3. Comparison to existing biomarkers: The text highlights the discriminative ability of pTau217 compared to existing biomarkers, such as amyloid positron emission tomography (PET) centiloid-based classification.

In conclusion, the text provides a valuable contribution to the field of AD research by highlighting the potential of pTau217 as a plasma-based biomarker for Aβ burden. The findings of this study have significant implications for the early detection of AD, the development of personalized treatment strategies, and the monitoring of treatment response. While the text builds upon existing knowledge, the novel application of pTau217 as a biomarker and the comparison to existing biomarkers provide valuable insights into its clinical utility.

Read the original article on medRxiv


Please, help us continue to provide valuable information: